Amjevita(adalimumab-atto)

Rheumatoid arthritis; psoriatic arthritis; juvenile idiopathic arthritis; ankylosing spondylitis; Crohn’s disease; plaque psoriasis; ulcerative colitis. TNF blocker biosimilar of Humira.

1 DTP program

From $299/mo cash · $0/mo copay card

1 platform

FDA-Approved Indications

Moderately-to-severely active rheumatoid arthritis in adultsModerate-to-severe plaque psoriasis in adultsModerately-to-severely active Crohn's disease in adultsModerately-to-severely active ulcerative colitis in adults

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

Cash-pay + copay card (insured)

via AmgenNow · Amgen

$299/mo cash · $0/mo copay card

Cash: $299/mo (2 autoinjectors 40mg/0.4mL). Other formulations: $527–$3,323. Copay card: $0/mo for commercially insured.

Eligibility

US patient with valid Rx. Government-insured must waive govt insurance for ALL Amgen Rx for the calendar year. CA/MA biosimilar rules may apply.

Must waive government insurance for all Amgen medications for the entire calendar year.

Some benefits may not be available in: MA, CA

Visit Program

Last verified: Mar 2026

Not sure which Amjevita program fits your situation?

Find My Options